Across TCGA pan-cancer cohorts, SPATA32 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SPATA32 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SPATA32 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SPATA32 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA and SKCM are the cancer types where SPATA32 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	1.000	0.326	.034	4	view →
SKCM	DFS	Median	All	0.078	0.211	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SPATA32 tumor-vs-normal RNA expression · all SPATA32 data types